All the Right Cells.
All the Time.
All Ways Guaranteed.

AllCells provides a reliable source of blood-derived cells and services for immuno- and cell therapy development.

Access any donor profile through LeukoLab, our adjacent wholly-owned blood donor facility and specify your subtype for immediate shipment or analysis service. Start reducing costs and attrition in your drug discovery programs. Conveniently browse our product lines:

Your Complete Hematology/Immunology Research Partner

On-Site Tissue Collection Facilities

Adjacent wholly-owned blood donor facility, LeukoLab, attracts diverse donor profiles needed for drug discovery programs. Featuring operations in SF Bay Area, CA and Boston, MA with shipping worldwide.

Primary Hematology and Immunology Cells

AllCells serves as a reliable provider of more than 150 primary cell types and whole tissues. Learn more here.

Customized Products

As your custom hematological/immunological primary cells provider, AllCells offers a variety of options to create the perfect application-ready cells/tissue based on your requirements. Learn more here.

Home_Resources_049Support

Visit our Support page for multiple resources including: information on how to ensure the best results while using our products, webinars, publications, shopping/delivery info, and requests for documentation.

News and Events

Nov 08, 2018
Society for Immunotherapy of Cancer Annual Meeting...
READ MORE
 
Sep 04, 2018
Boston Biotech Week - Cell & Gene Therapy Biop...
READ MORE
 
May 04, 2018
American Association of Immunologists, May 4-8 201...
READ MORE
 
May 02, 2018
International Society for Cell Therapy Annual Meet...
READ MORE
 
Apr 30, 2018
Protein Engineering Summit - PEGS, 2018, April 30 ...
READ MORE
 
Apr 14, 2018
AACR - American Association for Cancer Research An...
READ MORE
 
Mar 11, 2018
Bioprocess International West, 2018, March 19 - 22...
READ MORE
 
Jan 22, 2018
Cell & Gene Therapy World, 2018, Jan 22 - 25...
READ MORE
 
Dec 18, 2017
Representatives from AllCells will be participatin...
READ MORE
 
Oct 02, 2017
POSTED October 4, 2017 07:00 AM Eastern Standard T...
READ MORE